Laxxon Medical to Showcase LXM.2, a Novel 3D Printed GLP-1 Agonist at BIO 2024

 Laxxon Medical, a US-based pharma-technology company pioneering a new generation of advanced pharmaceuticals through novel 3D screen-printing platform technology SPID®, announced today its participation in the 2024 BIO International Convention on June 3-6, 2024 in San Diego, CA. The Company will be showcasing its LXM.2 asset to potential partners.

Visit here for more details: https://www.laxxonmedical.com/post/laxxon-medical-to-showcase-lxm-2-a-novel-3d-printed-glp-1-agonist-at-bio-2024

Comments

Popular posts from this blog

Drug Patents and Drug Exclusivity

The Impact of Water Filtration Systems on Family Health: Safeguarding All Generations

Advanced AI-Powered SEO Techniques Unveiled